Proactive Investors - Run By Investors For Investors
Why invest in REDX?
Redx Pharma Plc: DEEP DIVE
OVERVIEW

Redx Pharma: Developing treatments for cancer and fibrosis

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
researcher at microscope
OVERVIEW: REDX The Big Picture
The cancer drug is in the clinic, while a fibrosis treatment should be ready to enter the clinic a year from now
  • Cancer drug in the clinic 
  • Promising fibrosis treatments targeting large markets

What the company does 

Redx Pharma Plc (LON:REDX) is an early-stage drug developer that is bringing through treatments for cancer and fibrosis.

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division. Now, not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1s, which lower or break cancer’s defence against the body’s immune system. That’s why Redx plans to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

In parallel it is developing potential fibrosis treatments. RXC006 is designed to tackle a condition called idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease. ROCK2 has been developed to treat non-alcoholic liver disease, while it is also targeting Crohn’s Disease-related fibrosis.

RXC004

After a false start, Redx is resuming its phase I clinical trial. The trial is split in two: phases Ia and Ib. The former is focused on finding the safest most effective dose, while the latter will seek efficacy data.  The phase Ia will take place over the next 12-18 months, working with advanced cancer patients. The lead investigator is Dr Natalie Cook, of the Christie Hospital, Manchester. The other centres are The Marsden and Guys (London), Oxford and Newcastle.

Value kickers

  • RXC004 Ib-ready in the first-half of next year
  • Fibrosis treatments target significant commercial markets
  • Phase 1-ready idiopathic pulmonary fibrosis candidate ready to enter clinic in the next year

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use